Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BoNT-A for awake bruxism with temporomandibular disorder
RBR-62cftbpPhase 2Completed
- Sponsor
- Faculdade de Odontologia da Universidade do Estado do Rio de Janeiro
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of botulinum toxin type A in Awake Bruxism (AB) and temporomandibular disorder (TMD) (3 arms), sponsored by Faculdade de Odontologia da Universidade do Estado do Rio de Janeiro. Started Mar 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Awake Bruxism (AB)temporomandibular disorder (TMD)
Beyond the preview
Go deeper on RBR-62cftbp.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-62cftbp.